GRALGRAIL, Inc.同业对比
GRAIL, Inc. 与SPDR S&P Biotech ETF 持仓的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:XBI 前十大持仓| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GRAL本股 | $3.4B#13 | — | 1.3x#1 | 22.8x#1 | 17.2%#5 | 79.9%#1 | -382.0%#4 | -16.1%#7 | — | — | 93.3%#4 | — |
| MRNA | $58.1B#1 | — | 8.6x#8 | 29.9x#3 | -39.9%#7 | 20.8%#6 | -158.1%#3 | -41.7%#11 | -54.6%#3 | — | 486.2%#1 | — |
| TWST | $9.0B#5 | — | 20.1x#12 | 23.8x#2 | 20.3%#4 | 62.8%#2 | -36.2%#1 | -17.4%#8 | -41.4%#2 | — | — | — |
| ORKA | $6.2B#9 | — | 5.6x#4 | — | — | -25.9%#8 | — | -9.5%#4 | — | — | — | — |
| KYMR | $9.7B#3 | — | 6.4x#6 | 246.9x#6 | -16.7%#6 | 39.1%#3 | -891.1%#6 | 20.6%#1 | — | — | — | — |
| VKTX | $3.4B#12 | — | 8.4x#7 | — | — | -227.1%#14 | — | -88.1%#13 | — | — | 24.7%#6 | — |
| ERAS | $5.4B#11 | — | 14.9x#9 | — | — | 23.0%#5 | — | -34.4%#10 | — | — | — | — |
| RVMD | $42.0B#2 | — | 16.1x#10 | — | — | -88.5%#12 | — | -43.4%#12 | — | — | 338.6%#2 | — |
| RYTM | $6.7B#7 | — | 65.4x#13 | 35.5x#4 | 45.8%#3 | 24.6%#4 | -101.2%#2 | -0.2%#3 | -133.8%#4 | — | — | — |
| CGON | $6.6B#8 | — | 6.4x#5 | 1627.1x#7 | 254.7%#2 | -82.9%#11 | -4722.1%#7 | -15.6%#6 | -18.8%#1 | — | — | — |
| SLS | $2.4B#14 | — | 17.1x#11 | — | -100.0%#9 | 13.0%#7 | — | -19.5%#9 | — | — | — | — |
| PCVX | $8.7B#6 | — | 3.2x#2 | — | — | -65.2%#10 | — | -0.0%#2 | — | — | — | — |
| DNTH | $5.7B#10 | — | 4.9x#3 | 2815.7x#8 | -67.3%#8 | -91.1%#13 | -8739.3%#8 | -13.9%#5 | — | — | 173.8%#3 | — |
| CYTK | $9.6B#4 | — | — | 109.6x#5 | 376.6%#1 | -33.2%#9 | -695.4%#5 | — | — | — | 39.5%#5 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议